Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

Therapeutic Advances in Hematology - Tập 10 - 2019
Guillaume Richard‐Carpentier1, Courtney D. DiNardo2
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston TX 77030, USA

Tóm tắt

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidine and decitabine, which have historically provided only short-lived and modest benefits. The oral B-cell lymphoma 2 inhibitor, venetoclax, Venetoclax, an oral B-cell lymphoma 2 (BCL2) inhibitor, is now approved by the USA Food and Drug Administration (FDA) in combination with LDAC or HMA in older AML patients ineligible for intensive chemotherapy. Is now approved by the US Food and Drug Administration for this indication. In the pivotal clinical trials evaluating venetoclax either in combination with LDAC or with HMA, the rates of complete remission (CR) plus CR with incomplete hematological recovery were 54% and 67%, respectively and the median overall survival (OS) was 10.4 months and 17.5 months, respectively, comparing favorably with outcomes in clinical trials evaluating single-agent LDAC or HMA. The most common adverse events with venetoclax combinations are gastrointestinal symptoms, which are primarily low grade and easily manageable, and myelosuppression, which may require delays between cycles, granulocyte colony-stimulating factor (G-CSF) administration, or decreased duration of venetoclax administration per cycle. A bone marrow assessment after the first cycle of treatment is critical to determine dosing and timing of subsequent cycles, as most patients will achieve their best response after one cycle. Appropriate prophylactic measures can reduce the risk of venetoclax-induced tumor lysis syndrome. In this review, we present clinical data from the pivotal trials evaluating venetoclax-based combinations in older patients ineligible for intensive chemotherapy, and provide practical recommendations for the prevention and management of adverse events associated with venetoclax.

Từ khóa


Tài liệu tham khảo

Swerdlow SH, 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Surveillance, Epideiomolgy and End Results Program. Cancer stat facts: leukemia-acute myeloid leukemia (AML). National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/amyl.html. (accessed 25 April 2018).

10.1182/blood-2016-08-733196

10.1002/cncr.22496

10.1200/JCO.2011.38.9429

10.1182/blood-2015-01-621664

10.1038/leu.2012.229

10.1182/blood-2013-04-496596

10.3324/haematol.2012.066613

10.1182/blood-2014-03-560557

10.1038/s41375-018-0312-9

10.1016/j.stem.2012.12.013

10.1158/2159-8290.CD-13-0609

10.1158/2159-8290.CD-16-0313

10.1158/1078-0432.CCR-15-3057

10.1038/leu.2017.243

10.1007/s00277-012-1537-8

10.3109/10428194.2014.910657

10.1182/blood-2018-08-868752

10.1200/JCO.18.01600

10.1182/blood-2018-99-113749

10.1016/j.clinthera.2017.01.003

10.3324/haematol.11575

10.1056/NEJMoa1513257

10.1016/j.ccr.2006.10.006

10.1200/JCO.2011.34.7898

10.1182/blood-2014-10-604975

10.1038/sigtrans.2017.12

Caenepeel S, 2018, Cancer Discov, 8, 1582, 10.1158/2159-8290.CD-18-0387

10.1038/s41375-018-0261-3

Han L, 2019, Haematologica, 2018, 205534

10.1016/j.ccell.2017.11.003

Daver N, 2017, Blood, 130, 813, 10.1182/blood.V130.Suppl_1.813.813

10.1158/0008-5472.CAN-15-1070

10.18632/oncotarget.22284

10.1056/NEJMoa1112304

10.1056/NEJMoa1301689

10.1056/NEJMoa1516192

10.1002/ajh.25198

10.1182/blood-2013-01-480228

10.1056/NEJMoa1716984

10.1182/blood-2017-04-779405

10.1038/nm.3788

DiNardo CD, 24th Annual Congress of the European Hematology Association, 97

10.1016/j.exphem.2018.06.138

Thông tin
Thông tin xuất bản

Therapeutic Advances in Hematology

Tập 10

Thông tin tác giả